Docket
117th Congress · HOUSE BILLBILL

H.R. 6832 — To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.

“To amend the Federal Food, Drug, and Cosmetic Act and the Defense Production Act of 1950 to prohibit the Federal Government from limiting State access to key therapies, such as monoclonal antibodies, and from prioritizing Federal contracts over State contracts relating to purchasing supplies to combat the COVID-19 pandemic.”

Health
Introduced Feb 25, 2022
Last action Feb 28, 2022
Pipeline · Bill → Law
Step 1
Introduced
Feb 25, 2022
Step 2
Referred
Feb 28, 2022
Financial Services · E&C
Step 3
Committee
Step 4
House floor
Step 5
Senate
Step 6
Resolve Changes
Step 7
Signed
SummaryNo summary available

No CRS summary available for this bill.

Provisions · 1 sectionsIntroduced in House
Timeline · 4 actions
Feb 28, 2022
Referred to the Subcommittee on Health.
Feb 25, 2022
Introduced in House
Feb 25, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 25, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.